Ann Surg Treat Res.  2021 Feb;100(2):59-66. 10.4174/astr.2021.100.2.59.

Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy

• Jeon YW
• Lim ST
• Gwak H
• Park SY
• Shin J
• Han HS
• Suh YJ

• KMID: 2512477
• DOI: http://doi.org/10.4174/astr.2021.100.2.59

Abstract

Purpose
Treatment with 4 cycles of docetaxel and cyclophosphamide (TC) in the adjuvant setting is associated with better outcomes than treatment with doxorubicin and cyclophosphamide (AC). However, Western guidelines have indicated that TC confers a high risk (>20%) of febrile neutropenia (FN), while AC confers an intermediate risk (10%–20%) of FN. Threrefore, we evaluated the incidence of FN and the clinical utilization of pegfilgrastim prophylaxis after adjuvant TC chemotherapy.
Methods
We categorized 201 patients who received adjuvant TC chemotherapy into 3 groups according to the method of prophylaxis and compared neutropenic events, other adverse events, and hospital care costs in the 3 groups.
Results
The incidence of grade 4 neutropenia decreased from 93.0% in patients without prophylaxis to 82.4% in those who received secondary prophylaxis and 16.7% in those who received primary prophylaxis. Although the incidence of FN was not different between patients without prophylaxis and patients who received secondary prophylaxis (15.7% and 14.9%), none of the patients who received primary prophylaxis developed FN. Moreover, a decrease in neutropenic events resulted in a significant decrease in the mean duration of neutropenia (2.50 days to 0.08 days, P < 0.001), the risk of hospitalization (29.8% to 2.2%, P < 0.001), and the mean total hospital care cost for all chemotherapy cycles (790.80 to 486.00 US dollars, P < 0.001).
Conclusion
The use of pegfilgrastim prophylaxis during adjuvant TC chemotherapy is associated with significant decreases in the incidence of neutropenic events, hospitalization, and hospital care cost compared to those seen in patients without prophylaxis.

Keyword

Breast neoplasms; Chemotherapy; Febrile neutropenia; Granulocyte colony-stimulating factor

Figure

• 

  Fig. 1 The absolute neutrophil count (ANC) changes after chemotherapy according to the use of prophylaxis with pegfilgrastim.

Reference

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687–1717. PMID: 15894097.

2. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010; 10:337. PMID: 20587042.

3. Pal SK, Childs BH, Pegram M. Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. Breast Cancer Res Treat. 2010; 119:25–32. PMID: 19795206.

4. Smith RE, Bryant J, DeCillis A, Anderson S. National Surgical Adjuvant Breast and Bowel Project Experience. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 2003; 21:1195–1204. PMID: 12663705.

5. Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006; 24:5381–5387. PMID: 17135639.

6. Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol. 2012; 30:2232–2239. PMID: 22614988.

7. Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. J Clin Oncol. 2009; 27:1177–1183. PMID: 19204201.

8. Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, et al. Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017; 35:2647–2655. PMID: 28398846.

9. Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, et al. West German Study PlanB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol. 2019; 37:799–808. PMID: 30785826.

10. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002; 62 Suppl 1:1–15.

11. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systemat ic review. J Cl in Oncol. 2007; 25:3158–3167.

12. National Comprehensive Cancer Networt (NCCN). Clinical practice guidelines in oncology for hematopoietic growth factors (NCCN Guidelines version 2.2020) [Internet]. Fort Washington, PA: NCCN;2020. cited 2020 Apr 7. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

13. Younis T, Rayson D, Thompson K. Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support Care Cancer. 2012; 20:2523–2530. PMID: 22252548.

14. Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, et al. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Breast Cancer Res Treat. 2020; 180:715–724. PMID: 32170634.

15. Weycker D, Barron R, Edelsberg J, Kartashov A, Lyman GH. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat. 2012; 133:301–310. PMID: 22270932.

16. Fernandes R, Mazzarello S, Stober C, Vandermeer L, Dudani S, Ibrahim MF, et al. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review. Breast Cancer Res Treat. 2017; 161:1–10. PMID: 27783280.

17. Li Y, Family L, Yang SJ, Klippel Z, Page JH, Chao C. Risk of febrile neutropenia associated with select myelosuppressive chemotherapy regimens in a large community-based oncology practice. J Natl Compr Canc Netw. 2017; 15:1122–1130. PMID: 28874597.

18. Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, et al. Relationship of systemic exposure to unbound docetaxel and neut ropenia. Cl in Pharmacol Ther. 2005; 77:43–53.

19. Hor SY, Lee SC, Wong CI, Lim YW, Lim RC, Wang LZ, et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J. 2008; 8:139–146. PMID: 17876342.

20. Onoue H, Yano I, Tanaka A, Itohara K, Hanai A, Ishiguro H, et al. Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. Eur J Clin Pharmacol. 2016; 72:703–710. PMID: 26905999.

21. Kim CG, Sohn J, Chon H, Kim JH, Heo SJ, Cho H, et al. Incidence of febrile neutropenia in Korean female breast cancer patients receiving preoperative or postoperative doxorubicin/cyclophosphamide followed by docetaxel chemotherapy. J Breast Cancer. 2016; 19:76–82. PMID: 27064666.

22. Barcenas CH, Niu J, Zhang N, Zhang Y, Buchholz TA, Elting LS, et al. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol. 2014; 32:2010–2017. PMID: 24868022.